Efficacy and safety of switching from thrice daily glinide or alpha-GI to twice daily mitiglinide/voglibose combined drug in type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2014
At a glance
- Drugs Mitiglinide/voglibose (Primary) ; Alpha-glucosidase inhibitors; Meglitinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 Jul 2013 New trial record